Thryv Therapeutics

Thryv Therapeutics is pioneering a precision medicine approach to treat genetic and drug-induced Long QT syndromes, atrial fibrillation and oncology. Central to Thryv’s approach is the use of SGK1 inhibitors - SGK1 is a protein kinase which regulates a number of ion currents in human cardiac cells and supports cell survival and proliferation in many resistant cancer cells. Thryv has rapidly advanced their portfolio of SGK1 inhibitors and have completed a Phase 1 healthy volunteer study for LQT-1213.

Jobs: